Adjuvatis

Founded in December 2013, Adjuvatis is specialized in the development, manufacturing and formulation of a safe-by-design delivery system, called i-Particles®. Based on fully metabolizable ans biocompatible particles, this technology was initially developed by a joint research unit involving both the French National Center for Scientific Research (CNRS) and bioMérieux company, a global leader in in vitro diagnostics. Ten years of development and international evaluation raised interests and promising prospects in many healthcare fields and led to the creation of Adjuvatis. From R&D to production, Adjuvatis is operating services for Active Pharmaceutical Ingredients (APIs) and antigens formulation in the fields of vaccines, antibody generation and drug delivery (for cosmetics, dermatology, oncology and more). To fulfill the formulation development, Adjuvatis provides analytical services for customers’ formulations and colloidal technologies.